Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
To demonstrate bioequivalence of a 2.5 mg saxagliptin/1000 mg metformin (glucophage)
immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet
and 1000 mg metformin IR tablet co-administered to healthy subjects in a fasted and in a fed
state.